The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, named mFlusiva (mRNA-1010), for adults aged 50 and over. This approval follows an initial refusal by the FDA to review the vaccine, a decision that was later reversed. Clinical trials indicated that mFlusiva was superior to existing flu vaccines in preventing influenza-like illness, though it did report more frequent mild to moderate side effects such as injection-site pain and fatigue. AI
IMPACT This approval marks a significant step for mRNA technology beyond COVID-19 vaccines, potentially accelerating its adoption for other infectious diseases.
RANK_REASON Product approval by a major regulatory body for a novel vaccine technology. [lever_c_demoted from significant: ic=1 ai=0.4]
- mFlusiva
- Moderna
- mRNA-1010
- Richard Hughes IV
- The Guardian
- United States Food and Drug Administration
- World Health Organization
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
